Exploring Altimmune, Inc. (ALT) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Altimmune, Inc. (ALT) and why? Are institutional investors calling the shots, or is it the retail crowd fueling the stock? As of April 17, 2025, the share price stood at $4.55, a 34.15% dip from $6.91 on April 19, 2024. But don't let that sway you just yet! With 330 institutional owners holding a total of 45,936,517 shares, understanding the investor profile could unlock key insights into Altimmune's potential. Are these investors betting on the long-term success of pemvidutide, Altimmune's lead drug candidate, or are other factors at play?

Altimmune, Inc. (ALT) Who Invests in Altimmune, Inc. (ALT) and Why?

Understanding the investor profile of Altimmune, Inc. (ALT) involves examining the various types of investors who hold the company's stock and their motivations. This includes looking at retail investors, institutional investors, and hedge funds, each of which may have different investment strategies and objectives.

Key Investor Types

The investor base of Altimmune, Inc. (ALT) can be broadly categorized into:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. Their investment decisions can be influenced by factors such as news, market trends, and personal financial goals.
• Institutional Investors: These include entities such as mutual funds, pension funds, insurance companies, and investment firms that manage large sums of money on behalf of others. Institutional investors often conduct extensive research and analysis before making investment decisions.
• Hedge Funds: These are investment partnerships that use a variety of strategies, including leverage, derivatives, and short selling, to generate returns. Hedge funds tend to be more aggressive in their investment approach and may have a shorter investment horizon.

Investment Motivations

Investors are attracted to Altimmune, Inc. (ALT) for various reasons, often tied to the company's potential in the biopharmaceutical industry. Key motivations include:

• Growth Prospects: Altimmune, Inc. (ALT) is focused on developing novel therapeutic products, particularly in areas like obesity, liver diseases, and immune modulating therapies. Positive clinical trial results and regulatory approvals can drive significant stock appreciation.
• Market Position: As a company developing innovative therapies, Altimmune, Inc. (ALT) aims to establish a strong market position in its target areas. Success in clinical development and commercialization can lead to a competitive advantage.

Investment Strategies

The strategies employed by investors in Altimmune, Inc. (ALT) can vary widely:

• Long-Term Holding: Some investors, particularly institutional investors, may adopt a long-term holding strategy, based on the belief in the company's future growth potential and the long-term value of its pipeline.
• Short-Term Trading: Other investors, such as some hedge funds and retail traders, may engage in short-term trading, seeking to profit from short-term price fluctuations driven by news events, clinical trial updates, or market sentiment.
• Value Investing: Value investors may see Altimmune, Inc. (ALT) as undervalued based on its current stock price relative to its potential future earnings or the value of its assets, including its intellectual property and pipeline of drug candidates.

Understanding the composition and motivations of Altimmune, Inc. (ALT)'s investor base provides valuable insights into market sentiment and potential future stock performance. Different investor types bring different perspectives and strategies, which collectively influence the company's market dynamics.

For more insights into Altimmune, Inc. (ALT), explore: Mission Statement, Vision, & Core Values of Altimmune, Inc. (ALT).

Altimmune, Inc. (ALT) Institutional Ownership and Major Shareholders of Altimmune, Inc. (ALT)

Institutional ownership in Altimmune, Inc. (ALT) provides insights into the company's stability and investor confidence. Examining the top institutional investors, changes in ownership, and the overall impact they have can help to understand the dynamics influencing Altimmune's stock price and strategic direction.

As of the latest data, several institutional investors hold significant stakes in Altimmune, Inc. (ALT). Here’s a list of some of the top institutional holders:

• Vanguard Group Inc.
• BlackRock Fund Advisors
• State Street Global Advisors, Inc.
• RA Capital Management, L.P.
• FMR LLC

These firms manage substantial assets and their investment decisions can significantly influence market sentiment. Data regarding the exact shareholdings of these institutions can fluctuate frequently, it is recommended to consult the latest financial reports and filings for the most up-to-date figures.

Institutional investors frequently adjust their positions based on Altimmune's performance, potential, and broader market conditions. Recent changes in ownership can signal shifts in investor sentiment:

• Increased Stakes: An increase in institutional holdings may indicate positive expectations regarding Altimmune's future prospects, such as successful clinical trial outcomes or strategic partnerships.
• Decreased Stakes: Conversely, a decrease in holdings could reflect concerns about regulatory hurdles, financial performance, or competitive pressures.

Monitoring these changes can provide valuable insights into the evolving perspectives of sophisticated investors.

The presence and activities of large institutional investors can have a profound impact on Altimmune's stock price and overall strategy:

• Price Stability: Significant institutional ownership can reduce stock price volatility, as these investors often have a long-term investment horizon.
• Strategic Influence: Major shareholders may engage with Altimmune’s management, influencing corporate strategy, research and development priorities, and capital allocation decisions.
• Market Confidence: High institutional ownership can enhance market confidence, attracting additional investors and potentially lowering the cost of capital for Altimmune.

Understanding these dynamics is crucial for investors looking to assess the potential risks and rewards associated with Altimmune, Inc. (ALT). For more information on Altimmune's strategic direction, you might find this resource helpful: Mission Statement, Vision, & Core Values of Altimmune, Inc. (ALT).

Altimmune, Inc. (ALT) Key Investors and Their Impact on Altimmune, Inc. (ALT)

Understanding the investor profile of Altimmune, Inc. (ALT) provides valuable insights into the company's stability, growth potential, and market sentiment. Examining who is investing and their recent activities can offer a glimpse into the perceived value and future prospects of the company.

While specific real-time data on all individual investors is dynamic and often proprietary, focusing on institutional ownership and significant stakeholders provides a comprehensive overview. Recent moves by major investors can significantly influence stock movements and company decisions.

Institutional investors often hold substantial stakes in companies like Altimmune, Inc. (ALT). These investors include:

• Mutual Funds: Fidelity, Vanguard, BlackRock are examples of mutual fund companies that may hold shares.
• Hedge Funds: These funds, like Citadel or Point72, are known for taking large positions and can sometimes influence company strategy.
• Pension Funds: Public and private pension funds invest in companies to generate returns for their beneficiaries.
• Investment Banks: Goldman Sachs or JP Morgan Chase may hold shares as part of their investment portfolios.

The influence of these investors can be seen in several ways:

• Stock Price Volatility: Large purchases or sales can cause fluctuations in the stock price.
• Corporate Governance: Major shareholders can influence decisions such as executive compensation, board composition, and strategic direction.
• Mergers and Acquisitions: Significant investors can play a crucial role in supporting or opposing potential M&A deals.

Recent moves by key investors are critical to monitor. For example:

• Buying/Selling Large Stakes: A substantial increase or decrease in ownership by a major investor can signal confidence or concern about the company's future.
• Activism: Activist investors may publicly push for changes in company strategy or operations to increase shareholder value.

To illustrate the types of data that are relevant, consider the following hypothetical table showing institutional ownership (note: this is an example and not current, real data):

Analyzing such data helps in understanding market sentiment and potential future movements of the stock. Monitoring these investors and their actions can provide valuable insights for current and prospective shareholders of Altimmune, Inc. (ALT).

To gain more insights into the core values and objectives of the company, explore: Mission Statement, Vision, & Core Values of Altimmune, Inc. (ALT).

Altimmune, Inc. (ALT) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Altimmune, Inc. (ALT). This analysis encompasses major shareholders' attitudes, recent market behavior, and expert insights to provide a comprehensive investor profile.

As of April 17, 2025, Altimmune, Inc. (ALT) has 330 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 45,936,517 shares.

The largest shareholders include:

• BlackRock, Inc.
• Ameriprise Financial Inc
• Vanguard Group Inc
• State Street Corp
• Tang Capital Management Llc
• VTSMX - Vanguard Total Stock Market Index Fund Investor Shares
• IWM - iShares Russell 2000 ETF
• XBI - SPDR(R) S&P(R) Biotech ETF
• Geode Capital Management, Llc
• VEXMX - Vanguard Extended Market Index Fund Investor Shares

Institutional ownership accounts for 52.65% of Altimmune's shares. Major institutions, defined as those managing over $100 million in assets, are required to file their holdings with the SEC. These filings offer insights into market sentiment and potential volatility.

Recent analyst ratings point to a positive outlook. As of April 19, 2025, 13 analysts have given Altimmune (ALT) a 'Buy' consensus rating. Approximately 54% of analysts recommend a 'Strong Buy', 31% recommend 'Buy', and 15% suggest 'Hold'.

The average analyst price target for Altimmune Inc. in the past 3 months is $21.86. The highest analyst price target is $28.00, while the lowest forecast is $12.00. The average price target represents 380.44% increase from the current price of $4.55.

Recent market reactions reflect a mix of optimism and concern. On April 16, 2025, the share price was $4.40, an increase of 4.02% from the prior week, with a market capitalization of $348.87 million. However, the stock has shown a -40.52% decrease over the last year.

The ownership structure of Altimmune (ALT) stock is a mix of institutional, retail, and individual investors. Approximately 8.07% of the company's stock is held by institutional investors, 0.90% is held by insiders, and 67.28% is held by retail investors.

Significant changes in institutional holdings can influence the stock price. For example, Blackrock, Inc. held 6,159,305 shares as of December 31, 2024, an increase of 693,211 shares or 12.682%. Ameriprise Financial Inc. held 5,254,898 shares, an increase of 1,378,854 shares or 35.574%. Conversely, Vanguard Group Inc. decreased its holdings by -552,246 shares, a -11.081% change, holding 4,431,612 shares.

Recent news includes:

• William Blair initiated coverage of Altimmune (ALT) with a Market Perform recommendation on February 28, 2025.
• Stifel initiated coverage of Altimmune (ALT) with a Buy recommendation on January 8, 2025.
• UBS initiated coverage of Altimmune (ALT) with a Buy recommendation on November 13, 2024.

However, Altimmune Inc. reported a net loss of $23.2 million in the fourth quarter of 2024, highlighting financial challenges. The company's lead candidate, pemvidutide, faces clinical and commercialization risks, including competition and market adoption concerns.

Here's a summary of institutional ownership changes as of December 31, 2024:

In conclusion, investor sentiment towards Altimmune, Inc. (ALT) appears cautiously optimistic, supported by positive analyst ratings and increasing institutional ownership in some key firms. However, financial challenges and market competition introduce elements of risk. Understanding these dynamics is essential for making informed investment decisions. For more insights into the company's vision, refer to Mission Statement, Vision, & Core Values of Altimmune, Inc. (ALT).